Shorter, smarter treatment for lung cancer shows promise
NCT ID NCT03523702
First seen Mar 12, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study tested a new approach for people with advanced non-small cell lung cancer whose tumors have high levels of a protein called PD-L1. Instead of standard chemotherapy plus radiation, participants received immunotherapy (pembrolizumab) followed by a personalized 4-week course of radiation. The goal was to see if this combination could better control the cancer and delay its spread. The trial involved 25 adults and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
Conditions
Explore the condition pages connected to this study.